SEC Form 4 · accession 0001209191-19-012998
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julia P Gregory
Director
Period of report
Feb 21, 2019
Accepted (ET)
Feb 25, 2019 · 4:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Feb 21, 2019 | M | 12,000 | $23.63 | A | 12,000 | D | |
| Common SharesF2 | Feb 21, 2019 | S | 12,000 | $43.56 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $23.63 | Feb 21, 2019 | M | 12,000 | D | — | Aug 1, 2027 | Common Shares | 12,000 | 24,000 | D |
Explanation of responses
- F1This exercise and the subsequent sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 22, 2019.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 - $44.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F3This option grant was made pursuant to the Issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on August 2, 2018, 2019 and 2020, subject to the Reporting Person's continuous service with the Issuer at each vesting date.